Differentiation of multipotent neural stem cells derived from Rett syndrome patients is biased toward the astrocytic lineage

Molecular Brain

Volumn 8, Issue 1, 2015, Pages

  Andoh Noda, Tomoko ^a,b   Akamatsu, Wado ^b,c   Miyake, Kunio ^a   Matsumoto, Takuya ^b   Yamaguchi, Ryo ^b,d   Sanosaka, Tsukasa ^b   Okada, Yohei ^b,e   Kobayashi, Tetsuro ^f   Ohyama, Manabu ^f   Nakashima, Kinichi ^g   Kurosawa, Hiroshi ^a   Kubota, Takeo ^a   Okano, Hideyuki ^b  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JUNTENDO UNIVERSITY   (Japan)

^d Sumitomo Dainipponn Pharma Co Ltd   (Japan)

^e AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f KEIO UNIVERSITY   (Japan)

^g KYUSHU UNIVERSITY   (Japan)

Author keywords

Astrocytes; DNA methylation; Induced pluripotent stem cell; Methyl CpG binding protein 2 MeCP2; Neural stem cell; Rett syndrome

Indexed keywords

GLIAL FIBRILLARY ACIDIC PROTEIN; METHYL CPG BINDING PROTEIN 2; MUTANT PROTEIN; PROTEIN BINDING;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTROCYTE; CELL LINEAGE; CELL SPECIFICITY; CONTROLLED STUDY; DEVELOPMENTAL STAGE; EMBRYO; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC DISORDER; GLIAL FIBRILLARY ACIDIC PROTEIN GENE; HUMAN; HUMAN CELL; INDUCED PLURIPOTENT STEM CELL; MECP2 GENE; MONOZYGOTIC TWINS; MOUSE; MULTIPOTENT STEM CELL; NERVE CELL DIFFERENTIATION; NEURAL STEM CELL; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RETT SYNDROME; CELL DIFFERENTIATION; CELL LINE; CHILD; DNA METHYLATION; FIBROBLAST; GENETICS; METABOLISM; MOSAICISM; MUTATION; PATHOLOGY; X CHROMOSOME INACTIVATION;

ASTROCYTES; CELL DIFFERENTIATION; CELL LINE; CELL LINEAGE; CHILD; DNA METHYLATION; FIBROBLASTS; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INDUCED PLURIPOTENT STEM CELLS; METHYL-CPG-BINDING PROTEIN 2; MOSAICISM; MULTIPOTENT STEM CELLS; MUTATION; NEURAL STEM CELLS; PROTEIN BINDING; RETT SYNDROME; TWINS, MONOZYGOTIC; X CHROMOSOME INACTIVATION;

EID: 84929774376     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/s13041-015-0121-2     Document Type: Article

References (53)

1. Fabio RA, Giannatiempo S, Antonietti A, Budden S. The role of stereotypies in overselectivity process in Rett syndrome. Res Dev Disabil. 2009; 30: 136-45.
2. Hagberg B, Aicardi J, Dias K, Ramos O. A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: report of 35 cases. Ann Neurol. 1983; 14: 471-9.
3. Bienvenu T, Philippe C, De Roux N, Raynaud M, Bonnefond JP, Pasquier L, et al. The incidence of Rett syndrome in France. Pediatr Neurol. 2006; 34: 372-5.
4. Webb T, Clarke A, Hanefeld F, Pereira JL, Rosenbloom L, Woods CG. Linkage analysis in Rett syndrome families suggests that there may be a critical region at Xq28. J Med Genet. 1998; 35: 997-1003.
5. Amir RE, Van den Veyver IB, Wan M, Tran CQ, Francke U, Zoghbi HY. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat Genet. 1999; 23: 185-8.
6. Monteggia LM, Kavalali ET. Rett syndrome and the impact of MeCP2 associated transcriptional mechanisms on neurotransmission. Biol Psychiatry. 2009; 65: 204-10.
7. Ng HH, Zhang Y, Hendrich B, Johnson CA, Turner BM, Erdjument-Bromage H, et al. MBD2 is a transcriptional repressor belonging to the MeCP1 histone deacetylase complex. Nat Genet. 1999; 23: 58-61.
8. Agarwal N, Becker A, Jost KL, Haase S, Thakur BK, Brero A, et al. MeCP2 Rett mutations affect large scale chromatin organization. Hum Mol Genet. 2011; 20: 4187-95.
9. Chen WG, Chang Q, Lin Y, Meissner A, West AE, Griffith EC, et al. Derepression of BDNF transcription involves calcium-dependent phosphorylation of MeCP2. Science. 2003; 302: 885-9.
10. Martinowich K, Hattori D, Wu H, Fouse S, He F, Hu Y, et al. DNA methylation-related chromatin remodeling in activity-dependent BDNF gene regulation. Science. 2003; 302: 890-3.
11. Horike S, Cai S, Miyano M, Cheng JF, Kohwi-Shigematsu T. Loss of silent-chromatin looping and impaired imprinting of DLX5 in Rett syndrome. Nat Genet. 2005; 37: 31-40.
12. Chahrour M, Jung SY, Shaw C, Zhou X, Wong ST, Qin J, et al. MeCP2, a key contributor to neurological disease, activates and represses transcription. Science. 2008; 320: 1224-9.
13. Miyake K, Hirasawa T, Soutome M, Itoh M, Goto Y, Endoh K, et al. The protocadherins, PCDHB1 and PCDH7, are regulated by MeCP2 in neuronal cells and brain tissues: implication for pathogenesis of Rett syndrome. BMC Neurosci. 2011; 12: 81.
14. Amir RE, Van den Veyver IB, Schultz R, Malicki DM, Tran CQ, Dahle EJ, et al. Influence of mutation type and X chromosome inactivation on Rett syndrome phenotypes. Ann Neurol. 2000; 47: 670-9.
15. Young JI, Zoghbi HY. X-chromosome inactivation patterns are unbalanced and affect the phenotypic outcome in a mouse model of rett syndrome. Am J Hum Genet. 2004; 74: 511-20.
16. Gibson JH, Williamson SL, Arbuckle S, Christodoulou J. X chromosome inactivation patterns in brain in Rett syndrome: implications for the disease phenotype. Brain Dev. 2005; 27: 266-70.
17. Takahashi K, Tanabe K, Ohnuki M, Narita M, Ichisaka T, Tomoda K, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell. 2007; 131: 861-72.
18. Hotta A, Cheung AY, Farra N, Vijayaragavan K, Seguin CA, Draper JS, et al. Isolation of human iPS cells using EOS lentiviral vectors to select for pluripotency. Nat Methods. 2009; 6: 370-6.
19. Marchetto MC, Carromeu C, Acab A, Yu D, Yeo GW, Mu Y, et al. A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell. 2010; 143: 527-39.
20. Muotri AR, Marchetto MC, Coufal NG, Oefner R, Yeo G, Nakashima K, et al. L1 retrotransposition in neurons is modulated by MeCP2. Nature. 2010; 468: 443-6.
21. Cheung AY, Horvath LM, Grafodatskaya D, Pasceri P, Weksberg R, Hotta A, et al. Isolation of MECP2-null Rett Syndrome patient hiPS cells and isogenic controls through X-chromosome inactivation. Hum Mol Genet. 2011; 20: 2103-15.
22. Kim KY, Hysolli E, Park IH. Neuronal maturation defect in induced pluripotent stem cells from patients with Rett syndrome. Proc Natl Acad Sci U S A. 2011; 108: 14169-74.
23. Ananiev G, Williams EC, Li H, Chang Q. Isogenic pairs of wild type and mutant induced pluripotent stem cell (iPSC) lines from Rett syndrome patients as in vitro disease model. PLoS One. 2011; 6: e25255.
24. Cheung AY, Horvath LM, Carrel L, Ellis J. X-chromosome inactivation in rett syndrome human induced pluripotent stem cells. Front Psychiatry. 2012; 3: 24.
25. Tanaka Y, Kim KY, Zhong M, Pan X, Weissman SM, Park IH. Transcriptional regulation in pluripotent stem cells by methyl CpG-binding protein 2 (MeCP2). Hum Mol Genet. 2014; 23: 1045-55.
26. Williams EC, Zhong X, Mohamed A, Li R, Liu Y, Dong Q, Ananiev GE, Mok JC, Lin BR, Lu J, Chiao C, Cherney R, Li H, Zhang SC, Chang Q. Mutant astrocytes differentiated from Rett syndrome patients-specific iPSCs have adverse effects on wild-type neurons. Hum Mol Genet. 2014; 23: 2968-80.
27. Miyake K, Yang C, Minakuchi Y, Ohori K, Soutome M, Hirasawa T, et al. Comparison of Genomic and Epigenomic Expression in Monozygotic Twins Discordant for Rett Syndrome. PLoS One. 2013; 8: e66729.
28. Kubota T, Nonoyama S, Tonoki H, Masuno M, Imaizumi K, Kojima M, et al. A new assay for the analysis of X-chromosome inactivation based on methylation-specific PCR. Hum Genet. 1999; 104: 49-55.
29. Tchieu J, Kuoy E, Chin MH, Trinh H, Patterson M, Sherman SP, et al. Female human iPSCs retain an inactive X chromosome. Cell Stem Cell. 2010; 7: 329-42.
30. Ballas N, Lioy DT, Grunseich C, Mandel G. Non-cell autonomous influence of MeCP2-deficient glia on neuronal dendritic morphology. Nat Neurosci. 2009; 12: 311-7.
31. Skene PJ, Illingworth RS, Webb S, Kerr AR, James KD, Turner DJ, et al. Neuronal MeCP2 is expressed at near histone-octamer levels and globally alters the chromatin state. Mol Cell. 2010; 37: 457-68.
32. Colantuoni C, Jeon OH, Hyder K, Chenchik A, Khimani AH, Narayanan V, et al. Gene expression profiling in postmortem Rett Syndrome brain: differential gene expression and patient classification. Neurobiol Dis. 2001; 8: 847-65.
33. Setoguchi H, Namihira M, Kohyama J, Asano H, Sanosaka T, Nakashima K. Methyl-CpG binding proteins are involved in restricting differentiation plasticity in neurons. J Neurosci Res. 2006; 84: 969-79.
34. Kohyama J, Kojima T, Takatsuka E, Yamashita T, Namiki J, Hsieh J, et al. Epigenetic regulation of neural cell differentiation plasticity in the adult mammalian brain. Proc Natl Acad Sci U S A. 2008; 105: 18012-7.
35. Okabe Y, Kusaga A, Takahashi T, Mitsumasu C, Murai Y, Tanaka E, et al. Neural development of methyl-CpG-binding protein 2 null embryonic stem cells: a system for studying Rett syndrome. Brain Res. 2010; 1360: 17-27.
36. Okabe Y, Takahashi T, Mitsumasu C, Kosai K, Tanaka E, Matsuishi T. Alterations of gene expression and glutamate clearance in astrocytes derived from an MeCP2-null mouse model of Rett syndrome. PLoS One. 2012; 7: e35354.
37. Tsujimura K, Abematsu M, Kohyama J, Namihira M, Nakashima K. Neuronal differentiation of neural precursor cells is promoted by the methyl-CpG-binding protein MeCP2. Exp Neurol. 2009; 219: 104-11.
38. Namihira M, Nakashima K, Taga T. Developmental stage dependent regulation of DNA methylation and chromatin modification in a immature astrocyte specific gene promoter. FEBS Lett. 2004; 572: 184-8.
39. Forbes-Lorman RM, Kurian JR, Auger AP. MeCP2 regulates GFAP expression within the developing brain. Brain Res. 2014; 1543: 151-8.
40. Ran FA, Hsu PD, Wright J, Agarwala V, Scott DA, Zhang F. Genome engineering using the CRISPR-Cas9 system. Nat Protoc. 2013; 8: 2281-308.
41. Nagai K, Miyake K, Kubota T. A transcriptional repressor MeCP2 causing Rett syndrome is expressed in embryonic non-neuronal cells and controls their growth. Brain Res Dev Brain Res. 2005; 157: 103-6.
42. Kishi N, Macklis JD. MeCP2 functions largely cell-autonomously, but also non-cell-autonomously, in neuronal maturation and dendritic arborization of cortical pyramidal neurons. Exp Neurol. 2010; 222: 51-8.
43. Maezawa I, Swanberg S, Harvey D, LaSalle JM, Jin LW. Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions. J Neurosci. 2009; 29: 5051-61.
44. Chen RZ, Akbarian S, Tudor M, Jaenisch R. Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice. Nat Genet. 2001; 27: 327-31.
45. Duncan Armstrong D. Neuropathology of Rett Syndrome. J Child Neurol. 2005; 20: 747-53.
46. Chahrour M, Zoghbi HY. The story of Rett syndrome: from clinic to neurobiology. Neuron. 2007; 56: 422-37.
47. Sanacora G, Banasr M. From pathophysiology to novel antidepressant drugs: glial contributions to the pathology and treatment of mood disorders. Biol Psychiatry. 2013; 73: 1172-9.
48. Czeh B, Di Benedetto B. Antidepressants act directly on astrocytes: evidences and functional consequences. Eur Neuropsychopharmacol. 2013; 23: 171-85.
49. Ohta S, Imaizumi Y, Okada Y, Akamatsu W, Kuwahara R, Ohyama M, et al. Generation of human melanocytes from induced pluripotent stem cells. PLoS One. 2011; 6: e16182.
50. Chaddah R, Arntfield M, Runciman S, Clarke L, van der Kooy D. Clonal neural stem cells from human embryonic stem cell colonies. J Neurosci. 2012; 32: 7771-81.
51. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A. 1998; 95: 14863-8.
52. Saeed AI, Sharov V, White J, Li J, Liang W, Bhagabati N, et al. TM4: a free, open-source system for microarray data management and analysis. Biotechniques. 2003; 34: 374-8.
53. Kimura H, Hayashi-Takanaka Y, Goto Y, Takizawa N, Nozaki N. The organization of histone H3 modifications as revealed by a panel of specific monoclonal antibodies. Cell Struct Funct. 2008; 33: 61-73.